M0324 Alone or in Combination With Pembrolizumab or Chemotherapy in Advanced Cancers (TITER Study)
[vc_row][vc_column][vc_column_text css=""] Background: This study is testing a new experimental immunotherapy drug called M0324. This is the first time it is being given to people (a “first-in-human” study). Researchers want to learn how safe it is, how well patients tolerate it, and how the body processes the...
First-in-Human Study of BMS-986506 in People with Advanced Clear Cell Renal Cell Carcinoma
[vc_row][vc_column][vc_column_text css=""] Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. When the cancer has spread or returned after earlier treatments, options can become limited, and new therapies are needed. This study is testing a new experimental drug called BMS-986506. This is...
A Study of RO7502175 Alone or with Immunotherapy in Advanced Kidney and Urothelial Cancer of the Renal Pelvis
[vc_row][vc_column][vc_column_text css=""] Background: This is the first study in humans testing a new drug called RO7502175. Researchers want to learn if it is safe, how the body processes it, and whether it can help shrink or control cancer. The study includes people with several advanced or metastatic cancers—including...
Testing Immunotherapy Plus Chemotherapy in Urothelial Carcinoma of the Renal Pelvis
[vc_row][vc_column][vc_column_text css=""] Background: Urothelial carcinoma is the most common type of bladder cancer, but it can also start in other parts of the urinary system such as the kidney pelvis, ureter, or urethra. When the cancer has spread or cannot be removed by surgery, chemotherapy is usually...
A Study of Avelumab With or Without Cabozantinib After Chemotherapy for Advanced Urothelial Cancer of the Renal Pelvis
[vc_row][vc_column][vc_column_text css=""] Background: Avelumab is an immunotherapy that helps the immune system find and attack cancer cells. Cabozantinib is a targeted therapy that blocks certain proteins cancer cells need to grow and spread. Researchers think combining these two drugs may control the cancer better than immunotherapy alone. The Trial: The trial...
A Study of ST-02 for Treating Low-Grade Upper Tract Urothelial Carcinoma of the Renal Pelvis
[vc_row][vc_column][vc_column_text css=""] Background: Upper Tract Urothelial Carcinoma (UTUC) is a type of cancer that develops in the lining of the kidney or ureter (the tube that connects the kidney to the bladder). Standard treatments often involve surgery to remove part or all of the kidney and ureter,...
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory Renal medullary carcinoma
[vc_row][vc_column][vc_column_text css=""] Background: Some aggressive cancers have missing genes in their tumors, specifically SMARCB1 or SMARCA4. These types of tumors are often harder to treat and may not respond well to standard therapies. This study is testing two immunotherapy drugs: Tiragolumab blocks a protein called TIGIT, which activates the...
Stereotactic Radiation Therapy (SABR) With or Without Immunotherapy for Patients With Unresectable or Metastatic Kidney Cancer (SAMURAI)
[vc_row][vc_column][vc_column_text css=""] Background: Stereotactic body radiation therapy (SABR) is a type of radiation therapy that uses special equipment to deliver radiation to tumors with high precision. This method may kill tumor cells with few radiation doses over a shorter period, causing less damage to normal tissue. Immunotherapy, such...
A Study of MK-4700 Alone or With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
[vc_row][vc_column][vc_column_text css=""] Background: MK-4700 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works...
A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors
[vc_row][vc_column][vc_column_text css=""] Background: BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body's immune system to recognize and attack cancer cells. Since this...
A Study of BMS-986340 Alone or in Combination with Nivolumab for Patients with Advanced Kidney Cancer
Background: Nivolumab (Opdivo®) is a Health Canada-approved immunotherapy for the treatment of kidney cancer and works by targeting a molecule called PD-1. Blocking the PD-1 molecule helps prime the body’s immune defences to more effectively target and destroy cancer cells; these therapies are often called immune...
A Study of GSK4381562 Alone or in Combination with Dostarlimab or GSK4428859A for Patients with Advanced Kidney Cancer
Background: GSK4381562, Dostarlimab, and GSK4428859A belong to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Dostarlimab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab...
A Study of MDNA11 Alone or in Combination with Pembrolizumab in Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. MDNA11 is an experimental cancer therapy that...
A Study of KFA115 Alone or in Combination with Tislelizumab in Patients with Advanced Kidney Cancer
Background: Tislelizumab belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Tislelizumab targets the immune checkpoint molecule PD-1. This is similar to Nivolumab (Opdivo®), which is...
A Study of Combination Chemotherapy in Patients with Wilms Tumours
Background: Wilms tumour is a rare type of kidney cancer that primarily affects children. For most patients, the first line of treatment is surgery to remove the affected kidney (nephrectomy). This may be accompanied by either radiation treatment, chemotherapy, or both, depending on the size and...
A Study of OC-001 Alone or in Combination with a PD-L1 Inhibitor in Patients With Advanced Solid Tumours
Background: OC-001 is an experimental immunotherapy drug that works by targeting a molecule called TNF. This type of treatment works by preventing inflammation in the body and enhancing the anti-cancer effect of certain other treatments. Since this drug is still in the clinical trial phase, it has...
A Study for Patients with Advanced Kidney Cancer who are Currently on Treatment or in Follow-up for a Pembrolizumab Study (KEYNOTE-587)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. The purpose of this study is to assess...

























































